Added to YB: 2026-05-11
Pitch date: 2026-05-06
QURE [bullish]
uniQure N.V.
+22.44%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States.
Market Cap
$1.3B
Pitch Price
$22.59
Price Target
N/A
Dividend
N/A
EV/EBITDA
-7.79
P/E
-5.93
EV/Sales
69.79
Sector
Biotechnology
Category
value
Show full summary:
uniQure (QURE): Cash-Rich, Pipeline-Heavy, and Deeply Mispriced
QURE: Clinical-stage gene therapy at negative EV w/ $586.6M cash (runway to H2 2029). AMT-260 (epilepsy) Q2 2026 data readout catalyst. AMT-130 (HD) showed 75% slowing of progression at 36mo, UK MAA filing Q3 2026. FDA Type B meeting Q2 to negotiate new trial designs after initial rejection. Trading sub-$30 ignores clinical validation & balance sheet strength.
Read full article (3 min)